Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Adverum Biotechnologies stock | 11.56

Own Adverum Biotechnologies stock in just a few minutes.

Posted

Fact checked

Adverum Biotechnologies, Inc is a biotechnology business based in the US. Adverum Biotechnologies shares (ADVM) are listed on the NASDAQ and all prices are listed in US Dollars. Adverum Biotechnologies employs 114 staff and has a trailing 12-month revenue of around USD$250,000.

How to buy shares in Adverum Biotechnologies

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Adverum Biotechnologies. Find the stock by name or ticker symbol: ADVM. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Adverum Biotechnologies reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$11.56, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Adverum Biotechnologies, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Adverum Biotechnologies. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Adverum Biotechnologies's share price?

Since the stock market crash in March caused by coronavirus, Adverum Biotechnologies's share price has had significant negative movement.

Its last market close was USD$11.56, which is 22.13% down on its pre-crash value of USD$14.845 and 57.07% up on the lowest point reached during the March crash when the shares fell as low as USD$7.36.

If you had bought USD$1,000 worth of Adverum Biotechnologies shares at the start of February 2020, those shares would have been worth USD$1,019.63 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,135.54.

Adverum Biotechnologies share price

Use our graph to track the performance of ADVM stocks over time.

Adverum Biotechnologies shares at a glance

Information last updated 2020-10-20.
Latest market close USD$11.56
52-week range USD$6.58 - USD$26.98
50-day moving average USD$11.5194
200-day moving average USD$15.9591
Wall St. target price USD$27.38
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.046

Buy Adverum Biotechnologies shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Adverum Biotechnologies stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Adverum Biotechnologies price performance over time

Historical closes compared with the close of $11.56 from 2020-10-19

1 week (2020-11-19) -8.83%
1 month (2020-10-26) -2.69%
3 months (2020-08-26) -6.09%
6 months (2020-05-26) -43.44%
1 year (2019-11-26) 7.34%
2 years (2018-11-26) 214.13%
3 years (2017-11-24) 279.02%
5 years (2015-11-25) 16.18%

Adverum Biotechnologies financials

Revenue TTM USD$250,000
Gross profit TTM USD$-40,169,000
Return on assets TTM -20.86%
Return on equity TTM -37.87%
Profit margin 0%
Book value $3.504
Market capitalisation USD$1.1 billion

TTM: trailing 12 months

Shorting Adverum Biotechnologies shares

There are currently 12.4 million Adverum Biotechnologies shares held short by investors – that's known as Adverum Biotechnologies's "short interest". This figure is 17.7% up from 10.5 million last month.

There are a few different ways that this level of interest in shorting Adverum Biotechnologies shares can be evaluated.

Adverum Biotechnologies's "short interest ratio" (SIR)

Adverum Biotechnologies's "short interest ratio" (SIR) is the quantity of Adverum Biotechnologies shares currently shorted divided by the average quantity of Adverum Biotechnologies shares traded daily (recently around 1.4 million). Adverum Biotechnologies's SIR currently stands at 9.09. In other words for every 100,000 Adverum Biotechnologies shares traded daily on the market, roughly 9090 shares are currently held short.

However Adverum Biotechnologies's short interest can also be evaluated against the total number of Adverum Biotechnologies shares, or, against the total number of tradable Adverum Biotechnologies shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Adverum Biotechnologies's short interest could be expressed as 0.13% of the outstanding shares (for every 100,000 Adverum Biotechnologies shares in existence, roughly 130 shares are currently held short) or 0.1383% of the tradable shares (for every 100,000 tradable Adverum Biotechnologies shares, roughly 138 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Adverum Biotechnologies.

Find out more about how you can short Adverum Biotechnologies stock.

Adverum Biotechnologies share dividends

We're not expecting Adverum Biotechnologies to pay a dividend over the next 12 months.

Adverum Biotechnologies share price volatility

Over the last 12 months, Adverum Biotechnologies's shares have ranged in value from as little as $6.58 up to $26.98. A popular way to gauge a stock's volatility is its "beta".

ADVM.US volatility(beta: 1.68)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Adverum Biotechnologies's is 1.6839. This would suggest that Adverum Biotechnologies's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Adverum Biotechnologies overview

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). 7m8-aflibercept for the treatment of wet age-related macular degeneration; ADVM-043, an investigational gene therapy candidate for the treatment of alpha-1 antitrypsin deficiency; and ADVM-053, a preclinical gene therapy product candidate for the treatment of hereditary angioedema. The company has collaboration agreements with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Redwood City, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site